Zobrazeno 1 - 10
of 141
pro vyhledávání: '"Thomayant, Prueksaritanont"'
Autor:
Udomsak Udomnilobol, Wilasinee Dunkoksung, Watchara Sakares, Suree Jianmongkol, Thomayant Prueksaritanont
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Dabigatran etexilate (DABE) is a clinical probe substrate for studying drug-drug interaction (DDI) through an intestinal P-glycoprotein (P-gp). A recent in vitro study, however, has suggested a potentially significant involvement of CYP3A-mediated ox
Externí odkaz:
https://doaj.org/article/95f7abe01b0d4fe782a9783994c22379
Autor:
Nattiya Hirankarn, Trairak Pisitkun, Nonthaneth Nalinratana, Niphat Jirapongwattana, Udomsak Udomnilobol, Songkiat Songthammanuphap, Eakkaphon Rattanangkool, Nopparat Thavornsin, Sirikan Deesiri, Jakkrit Srisa, Jakapun Soponpong, Supanan Ampawa, Chayan Charoenpakdee, Wilasinee Dunkoksung, Tanachote Ruengsatra, Supranee Buranapraditkun, Tirayut Vilaivan, Thomayant Prueksaritanont
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/67ce0443e53248e29280baa9b4b0cfc0
Autor:
Punyabhorn Rattanacheeworn, Stephen J Kerr, Wonngarm Kittanamongkolchai, Natavudh Townamchai, Suwasin Udomkarnjananun, Kearkiat Praditpornsilpa, Thanundorn Thanusuwannasak, Udomsak Udomnilobol, Suree Jianmongkol, Boonsri Ongpipattanakul, Thomayant Prueksaritanont, Yingyos Avihingsanon, Pajaree Chariyavilaskul
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Background: Ageing and chronic kidney disease (CKD) affect pharmacokinetic (PK) parameters. Since mechanisms are related and remain unclear, cytochrome P450 (CYP) 3A and drug transporter activities were investigated in the elderly with or without CKD
Externí odkaz:
https://doaj.org/article/009bc8b1a9aa4cf6889e73b639ea2bfb
Publikováno v:
Drug Metabolism and Disposition. :DMD-AR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e07200ce156c28e213f8c73481fb342
https://doi.org/10.1124/dmd.123.001353
https://doi.org/10.1124/dmd.123.001353
Autor:
Christine Fandozzi, Deborah Panebianco, Luzelena Caro, Dennis Wolford, Zifang Guo, Iain P. Fraser, Dennis Swearingen, Vanessa Levine, Hwa-Ping Feng, Thomayant Prueksaritanont, Joan R. Butterton, Marian Iwamoto, Wendy W. Yeh
Publikováno v:
Clinical Drug Investigation. 41:133-147
Many people infected with hepatitis C virus have comorbidities, including hypercholesterolemia, that are treated with statins. In this study, we evaluated the drug–drug interaction potential of the hepatitis C virus inhibitors elbasvir (EBR) and gr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ebcf0ed8c8b4c9cc92692ec75038ce5
https://doi.org/10.1007/s40261-020-00974-8
https://doi.org/10.1007/s40261-020-00974-8
Autor:
Luzelena, Caro, Thomayant, Prueksaritanont, Christine M, Fandozzi, Hwa-Ping, Feng, Zifang, Guo, Dennis, Wolford, Deborah, Panebianco, Iain P, Fraser, Vanessa, Levine, Dennis, Swearingen, Joan R, Butterton, Marian, Iwamoto, Wendy W, Yeh
Publikováno v:
Clinical drug investigation. 41(2)
Many people infected with hepatitis C virus have comorbidities, including hypercholesterolemia, that are treated with statins. In this study, we evaluated the drug-drug interaction potential of the hepatitis C virus inhibitors elbasvir (EBR) and graz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9b418fcdc4e7326a59183564659736b7
https://pubmed.ncbi.nlm.nih.gov/33527237
https://pubmed.ncbi.nlm.nih.gov/33527237
Autor:
Nikunjkumar Patel, Arpar Ngampanya, Boonsri Ongpipattanakul, Suree Jianmongkol, Thomayant Prueksaritanont, Pakawadee Sermsappasuk, Udomsak Udomnilobol, Natapol Pornputtapong
Publikováno v:
Journal of pharmaceutical sciences. 110(5)
In this study, we aimed to develop and qualify a PBPK model for scalp application using two drugs with marked differences in physicochemical properties and PK profiles. The parameters related to scalp physiology, drug PK, and formulations were incorp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cc8f8925369e9b98f5eccc02715931a
https://pubmed.ncbi.nlm.nih.gov/33609522
https://pubmed.ncbi.nlm.nih.gov/33609522
Publikováno v:
Handbook of Drug Metabolism ISBN: 9780429190315
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30e26640d0d14ecb18c1296fc394a9ff
https://doi.org/10.1201/9780429190315-22
https://doi.org/10.1201/9780429190315-22
Autor:
Xiaodong Li, Tamara D. Cabalu, Cheri M Maciolek, Donghui Cui, Wen Liu, Ka Lai Yee, Thomayant Prueksaritanont, Sheri Smith, Bo Liu, Jacqueline B. McCrea, James H. Small
Publikováno v:
Xenobiotica. 46:882-895
1. Suvorexant (MK-4305, Belsomra®) is a first-in-class dual orexin receptor antagonist approved in the USA and Japan for the treatment of insomnia. The current studies describe suvorexant's absorption, disposition and potential for CYP-mediated drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40736ebb0dc90a36a7625a873ab333cb
https://doi.org/10.3109/00498254.2015.1129565
https://doi.org/10.3109/00498254.2015.1129565
Publikováno v:
Journal of Pharmaceutical Sciences. 104:916-929
Drug-drug interactions (DDIs) related to altered drug absorption and plasma protein binding have received much less attention from regulatory agencies relative to DDIs mediated via drug metabolizing enzymes and transporters. In this review, a number
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86a152f5cf99fb80400d7efd494f814a
https://doi.org/10.1002/jps.24306
https://doi.org/10.1002/jps.24306